$38.23
0.09% today
Nasdaq, Sep 23, 06:16 pm CET
ISIN
US00847X1046
Symbol
AGIO

Agios Pharmaceuticals, Inc. Stock price

$38.19
-0.61 1.57% 1M
+5.88 18.20% 6M
+5.33 16.22% YTD
-7.57 16.54% 1Y
+8.57 28.93% 3Y
+1.59 4.34% 5Y
-49.63 56.51% 10Y
+6.91 22.09% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.49 1.30%
ISIN
US00847X1046
Symbol
AGIO
Industry

Key metrics

Basic
Market capitalization
$2.2b
Enterprise Value
$1.3b
Net debt
positive
Cash
$938.9m
Shares outstanding
58.0m
Valuation (TTM | estimate)
P/E
3.4 | negative
P/S
54.3 | 49.2
EV/Sales
31.3 | 28.4
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
92.7%
Return on Equity
43.7%
ROCE
44.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$40.9m | $45.1m
EBITDA
$632.9m | $-487.7m
EBIT
$627.6m | $-498.1m
Net Income
$650.1m | $-437.4m
Free Cash Flow
$-409.0m
Growth (TTM | estimate)
Revenue
30.6% | 23.7%
EBITDA
258.6% | -16.1%
EBIT
254.9% | -17.0%
Net Income
278.1% | -164.9%
Free Cash Flow
-33.0%
Margin (TTM | estimate)
Gross
88.2%
EBITDA
1,548.3% | -1,080.5%
EBIT
1,535.4%
Net
1,590.4% | -969.2%
Free Cash Flow
-1,000.7%
More
EPS
$11.2
FCF per Share
$-7.0
Short interest
8.3%
Employees
487
Rev per Employee
$70.0k
Show more

Is Agios Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Agios Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

10x Buy
71%
4x Hold
29%

Analyst Opinions

14 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Agios Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
41 41
31% 31%
100%
- Direct Costs 4.83 4.83
45% 45%
12%
36 36
29% 29%
88%
- Selling and Administrative Expenses 178 178
39% 39%
435%
- Research and Development Expense 320 320
5% 5%
783%
633 633
259% 259%
1,548%
- Depreciation and Amortization 5.25 5.25
12% 12%
13%
EBIT (Operating Income) EBIT 628 628
255% 255%
1,535%
Net Profit 650 650
278% 278%
1,590%

In millions USD.

Don't miss a Thing! We will send you all news about Agios Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agios Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
15 days ago
Agios faces a pivotal FDA decision on 7 December for mitapivat's thalassemia expansion, with a good chance of approval based on strong Phase 3 data. The stock has lagged typical pre-PDUFA momentum, offering an attractive entry point for risk-tolerant investors ahead of a potential catalyst. Safety concerns exist but are likely manageable with enhanced monitoring; Agios' robust cash position pro...
Neutral
Seeking Alpha
19 days ago
Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain confident in mitapivat's strong efficacy and competitive oral profile, expecting eventual FDA approval in December. Agios is financially robust with $1.3bn cash, and approval could unlock blockbuster...
Neutral
GlobeNewsWire
19 days ago
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription...
More Agios Pharmaceuticals, Inc. News

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Goff
Employees 487
Founded 2007
Website www.agios.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today